NLRP3 inflammasome and its inhibitors: a review.

Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. · 2015

Read NLRP3 inflammasome and its inhibitors: a review. by Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4633676.txt.

Description

Working with colleagues, Bo-Zong Shao published a 2015 review of the NLRP3 inflammasome and drugs that block it. Inflammasomes are protein assemblies of the innate immune system that switch on inflammation. NLRP3 is the best studied member and reacts to many danger signals. The review appeared in Clinical and Experimental Pharmacology and Physiology.

NLRP3 activity is tied to metabolic disorders, multiple sclerosis, inflammatory bowel disease, and inherited fever syndromes, among others. The authors explain the complex's structure and what sets it off, then survey known blockers, some already promising in clinical testing. Autophagy, the cell's cleanup process, also features as a natural brake. The review gives drug developers a single map of the target and the compounds chasing it.

Catalog record

CREATORShao BZ, Xu ZQ, Han BZ, Su DF, Liu C.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4633676

Browse the full library · About the Tower of Babel